TAG:
BioReference Health
January 19, 2026, Intelligence: Late-Breaking Lab News
Entrepreneur Mark Cuban is calling for financial penalties to curb what he describes as systemic overbilling across the US healthcare system, a proposal that could significantly raise the stakes for insurers, hospitals, and clinical laboratories. In a provocative Dec. 24 post on X, Cuba…
National Lab Company Briefs
Quest, Labcorp Push Alzheimer’s Test Quest Diagnostics and Labcorp are now offering Fujirebio’s Lumipulse test, the first Food and Drug Administration-cleared blood-based assay for con…
Quest, Labcorp Discuss PAMA and M&A with Investors
WHILE LAUDING EXCELLENT GROWTH FOR THE SECOND QUARTER, executives at Labcorp and Quest Diagnostics also expressed concern over the Protecting Access to Medicare Act (PAMA), which was passed by Congress in 2014 and which continues to cause uncertainty as full implementation is repeatedly…
Quest, Labcorp CEOs Discuss Tariff Strategies with Investors
Leaders at Labcorp and Quest Diagnostics indicated that they are prepared to weather at least the early months of the unfolding tariff war that is upending the global economy. “There will be some impact from …
Federal Lawsuit Favors Lab Accused of AKS Violations
CEO SUMMARY: This whistleblower lawsuit initially charged a clinical lab with, among other things, violating the Anti-Kickback Statute and EKRA. After the judge ruled to exclude the AKS and EKRA claims, the whistleblower refiled the case and included claims the lab paid commissions for th…
Labcorp to Acquire Only Certain Lab Assets of OPKO’s BioReference
Following Labcorp’s announcement that it will acquire “select assets” of BioR…
July 31, 2023, Intelligence: Late-Breaking Lab News
Regulatory relief is on the way for clinical laboratories accredited by The Joint Commission. An overhaul of the Laboratory Accreditation Program’s standards, which goes into effect Aug. 27, will …
CURRENT ISSUE
Volume XXXIII, No. 7 – May 26, 2026
Momentum is building on Capitol Hill to pass the RESULTS Act, which would stave off drastic 15% reimbursement cuts under PAMA. Advocates seek lobbying help from clinical labs and anatomic pathology practices. Also, The Dark Report examines Roche’s deal to acquire PathAI.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.